High Quality Ep/USP Spectinomycin Hydrochloride

Product Details
Customization: Available
Type: Diagnosis & Injection
Color: White
Gold Member Since 2005

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Management System Certification
ISO 9001, ISO 14000, ISO 20000, GMP, HACCP
Terms of Payment
LC, T/T, Western Union
Find Similar Products

Basic Info.

Model NO.
SP
for Animal
Pig
Dosage Form
Powder
Function
Antibacterial Drugs
Transport Package
20kgs/Drum
Specification
EP/USP
Trademark
Fraken
Origin
China
Production Capacity
100mt Per Year

Product Description

Spectinomycin Hydrochloride

Chemistry - An aminocyclitol antibiotic obtained from Streptomyces spectabilis, specti­ Nomycin is available as the dihydrochloride pentahydrate. It occurs as a white to pale buff, crystalline powder with pKas of 7 and 8.7. It is freely soluble in water and practically in­ Soluble in alcohol.

Storage/Stability/Compatibility - Unless otherwise instructed by the manufacturer, spectinomycin products should be stored at room temperature (15-30° C).

Pharmacology - Spectinomycin is primarily a bacteriostatic antibiotic that inhibits protein synthesis in susceptible bacteria by binding to the 30S ribosomal subunit.

Spectinomycin has activity against a wide variety of gram positive and gram negative bacteria, including E. Coli, Klebsiella, Proteus, Enterobacter, Salmonella, Streptococci, Staphylococcus and Mycoplasma. It has minimal activity against anaerobes, most strains of Pseudomonas, Chlamydia, or Treponema. In human medicine, spectinomycin is used principally for its activity against Neissiera gonorrhoeae.

Uses/Indications - Although occasionally used in dogs, cats, horses and cattle for suscep­ Tible infections, spectinomycin is only approved for use in chickens, turkeys and swine. Refer to the Dosage section below for more information on approved uses.

Pharmacokinetics - After oral administration only about 7% of the dose is absorbed, but the drug that remains in the GI tract is active. When injected SQ or IM, the drug is report­ Edly well absorbed with peak levels occurring in about 1 hour.

Tissue levels of absorbed drug are lower than those found in the serum. Spectinomycin does not appreciably enter the CSF or the eye and is not bound significantly to plasma PRO­ Teins. It is unknown whether spectinomycin crosses the placenta or enters milk.

Absorbed drug is excreted via glomerular filtration into the urine mostly unchanged. No specific pharmacokinetic parameters were located for veterinary species.

Contraindications/Precautions/Reproductive Safety - Spectinomycin is contraindicated in patients hypersensitive to it. The reproductive safety of the drug is not known.

Adverse Effects/Warnings - When used as labeled, adverse effects are unlikely with this drug. It is reported that parenteral use of this drug is much safer than with other aminocy­ Clitol antibiotics, but little is known regarding prolonged use of the drug. It is probably safe to say that spectinomycin is significantly less ototoxic and nephrotoxic than other commonly used aminocyclitol antibiotics, but can cause neuromuscular blockade. Parenteral calcium administration will generally reverse the blockade.

Adverse effects that have been reported in human patients receiving the drug in single or multidose studies include soreness at injection site, increases in BUN, alkaline phos­ Phatase and SGPT, and decreases in hemoglobin, hematocrit and creatinine clearance. Although increases in BUN and decreases in creatinine clearance and urine output have been noted, overt renal toxicity has not been demonstrated with this drug.

Overdosage/Acute Toxicity - No specific information was located on oral overdoses, but because the drug is negligibly absorbed after oral administration, significant toxicity is un­ Likely via this route. Injected doses of 90 mg produced transient ataxia in Turkey poults.

Drug Interactions - Antagonism has been reported when spectinomycin is used with chloramphenicol or tetracycline.

Doses -
Horses:
For susceptible infections:
A) 20 mg/kg IM tid (Robinson 1987)
B) For pneumonia: 20 mg/kg IM q8h; May cause local myositis. Insufficient data to comment on use. (Beech 1987b)

Monitoring Parameters -
1) Clinical efficacy

No.
 

Item
 

Standard
 

Test Result
 

1
 

Appearance
 

white or almost white powder
 

Conforms
 

2
 

Specific Optical Rotation
 

15°21°
 

17°
 

3
 

Identification
 

Conforms
 

Conforms
 

4
 

Clarity Of Solution
 

Conforms
 

Conforms
 

5
 

Color Of Solution
 

Conforms
 

Conforms
 

6
 

PH
 

3.85.6
 

4.8
 

7
 

Water
 

16%20.0%
 

17.40%
 

8
 

Related Substances
 

Conforms
 

Conforms
 

9
 

Sulphate Ash
 

≤1.0%
 

0.40%
 

10
 

Bacterial Endotoxins
 

≤0.09EU/MG
 

Conforms
 

11
 

Assay(On Hydrous Basis)
 

95%100.5%
 

96.00%
 

12
 

Potency(On Hydrous Basis)
 

750U/MG800U/MG
 

787U/MG
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier